The University of Texas, MD Anderson Cancer Center
Welcome,         Profile    Billing    Logout  
 47 Trials 
83 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
25
US
AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin
M.D. Anderson Cancer Center, Arno Therapeutics
Myelodysplastic Syndrome
12/15
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Active, not recruiting
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
ALERTCML, NCT05143840: Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
8
US
Asciminib, ABL001, Ascimininb + Nilotinib, ABL001 + TASIGNA, Asciminib + Imatinib, ABL001 + Gleevec, Asciminib + Dasatinib, ABL001 + Sprycel
Augusta University, H. Jean Khoury Cure CML Consortium
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
02/25
02/27
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT05905328: Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Recruiting
1/2
54
US
CTO1681 10 μg, CTO1681 20 μg, CTO1681 30 μg
CytoAgents, Inc., TFS HealthScience
Cytokine Release Syndrome
06/27
06/27
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia

Checkmark Data from trial for AML at EHA 2020
Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020
Checkmark Initial data in AML
May 2020 - May 2020: Initial data in AML
Checkmark Planned clinical update
More
Active, not recruiting
1
62
Europe, US
MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3
Merus N.V.
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
07/21
07/21
P-TRP-2447-14, NCT02530034: Hu8F4 in Treating Patients with Advanced Hematologic Malignancies

Active, not recruiting
1
72
US
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
01/26
01/26
DiPersio, John F
GENESIS, NCT03246529 / 2018-001715-79: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Active, not recruiting
3
180
Europe, US
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
BioLineRx, Ltd.
Multiple Myeloma
12/20
09/29
NCT06483100: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Recruiting
2
65
US
Elrantamab, clonoSEQ
Washington University School of Medicine, National Comprehensive Cancer Network, Pfizer, Rapid Novor
Multiple Myeloma
12/31
12/31
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
07/26
07/26
NCT04582864: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Terminated
2
11
US
Flotetuzumab, MGD006, Donor lymphocyte infusion, DLI
Washington University School of Medicine, MacroGenics, National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia
03/24
07/24
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Withdrawn
2
48
NA
Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis
Washington University School of Medicine
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
09/26
07/28
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Withdrawn
2
35
NA
Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron
Washington University School of Medicine, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma-Associated Amyloidosis
01/27
01/27
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Active, not recruiting
2
17
US
Duvelisib, Copiktra, Peripheral blood draw
Washington University School of Medicine, SecuraBio
T-Cell Lymphoma
07/26
07/26
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting
2
107
US
Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology
Acute Myeloid Leukemia
07/29
07/29
CEDAR, NCT04819841: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Recruiting
1/2
15
US
nula-cel Drug Product
Kamau Therapeutics
Sickle Cell Disease
07/26
07/27
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
02/25
01/27
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
53
US
GDX012, Chemotherapy Agents
Takeda
Leukemia
04/26
06/27
NCT03687957: rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

Active, not recruiting
1/2
42
US
rhIL-7-hyFc, Placebo, Temozolomide, TMZ, Radiation therapy, RT, Blood sample
Washington University School of Medicine, NeoImmuneTech, The Foundation for Barnes-Jewish Hospital
Glioma
02/25
01/32
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated
1
1
US
Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone
Washington University School of Medicine, Sanofi
Multiple Myeloma
12/22
01/24
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Terminated
1
4
US
ApoGraft
Washington University School of Medicine, Cellect Biotechnology
Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant
12/22
12/22
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Hourglass Apr 2020 - Jun 2020 : From trial in combination with bendamustine for penta-refractory multiple myeloma
Terminated
1
15
US
Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol
Washington University School of Medicine, Sanofi
Multiple Myeloma
03/23
03/24
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Recruiting
1
10
US
Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis
Washington University School of Medicine, BioLineRx, Ltd., Biogen
Sickle Cell Disease
12/25
12/25
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Completed
1
55
US
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
04/24
05/24
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
NCT06185751: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Recruiting
1
25
US
WS-CART-CS1, Lymphodepleting chemotherapy
Washington University School of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research
Multiple Myeloma
08/29
08/40
NCT06547112: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Recruiting
1
20
US
Motixafortide, BL-8040, G-CSF
Washington University School of Medicine, BioLineRx, Ltd.
Multiple Myeloma
01/26
01/26
NCT06523699: Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

Not yet recruiting
1
30
US
Recombinant glycosylated human interleukin-7, CYT107, r-hIL-7, Melphalan, Autologous hematopoietic cell transplant, AHCT
Washington University School of Medicine, Revimmune
Multiple Myeloma
01/29
01/29
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Active, not recruiting
1
63
US
NC525
NextCure, Inc.
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
05/25
05/25
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Recruiting
1
43
US
Duvelisib
Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia
12/25
05/30
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Recruiting
1
15
US
Mosunetuzumab, RO7030816, BTCT4465A
Washington University School of Medicine, Genentech, Inc.
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
07/27
06/29
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting
1
49
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
09/26
12/26
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Recruiting
1
54
US
WU-CART-007
Washington University School of Medicine, Wugen, Inc.
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
04/26
04/26
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
NCT04614987: Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

Terminated
N/A
17
US
Washington University School of Medicine, McDonnell Center, Paula and Roger Riney Blood Cancer Research
Neurotoxicity
09/23
09/23
NCT02611180: Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Recruiting
N/A
50
US
Skin punch biopsy, Peripheral blood draw
Washington University School of Medicine
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
04/25
04/25
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Recruiting
N/A
165
US
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Washington University School of Medicine, Notable Labs
Acute Myeloid Leukemia, Myelodysplastic Syndromes
01/25
01/25
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33

Recruiting
N/A
36
Canada, US
VOR33
Vor Biopharma
Leukemia, Myeloid, Acute
01/40
01/40
Kim, Kevin
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
CPMC17-MEL01, NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Niraparib
California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute
Metastatic Melanoma
02/22
02/23
NCT04633902: Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Olaparib, Lynparza, Pembrolizumab, Keytruda
California Pacific Medical Center Research Institute, M.D. Anderson Cancer Center
Metastatic Melanoma
06/23
12/24
NCT05077280: A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

Recruiting
2
40
US
stereotactic body radiotherapy, Immunotherapy
California Pacific Medical Center Research Institute
Uveal Melanoma
03/24
03/26
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Active, not recruiting
1
140
US
AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus
AstraZeneca
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
08/10
12/24
NCT04601428: Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Recruiting
1
43
RoW
IA therapy of HCC with CSR02-Fab-TF
Koo Foundation Sun Yat-Sen Cancer Center
Hepatocellular Carcinoma (HCC)
12/24
12/24
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, not recruiting
1
123
Europe, US
RP3, Nivolumab
Replimune Inc., Bristol-Myers Squibb
Advanced Solid Tumor
11/26
11/26
NCT05740293: Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure

Active, not recruiting
N/A
171
US
VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism
Carl Zeiss Meditec, Inc.
Myopia, Astigmatism
09/24
03/25
Hagberg, Carin A
NCT03757091: Flexible Intubation Scope with or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients with Head and Neck Cancer Before Surgery

Recruiting
N/A
144
US
Laryngoscopy, Tracheal Intubation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Head and Neck Neoplasm
08/25
08/25
Ravi, Vinod
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
120
Europe, Canada, US, RoW
vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
MANEUVER, NCT05804045: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
90
Europe, Canada, US, RoW
Pimicotinib(ABSK021), Placebo
Abbisko Therapeutics Co, Ltd
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
05/26
06/28
NCT05026736: Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Active, not recruiting
2
6
US
Quality-of-Life Assessment, Quality of Life Assessment, Sintilimab, Anti-PD-1 Monoclonal Antibody IBI308, Anti-PDCD1 Monoclonal Antibody IBI308, IBI 308, IBI308
M.D. Anderson Cancer Center
Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma
12/27
12/27
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
NCT05799612: Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Withdrawn
1
24
NA
Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A, Filgrastim, G-CSF, NeupogenTM
M.D. Anderson Cancer Center, Cancer Cures 4 Kids
Angiosarcoma
11/24
11/24
NCT05216029: Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma

Active, not recruiting
N/A
92
US
Best Practice, standard of care, standard therapy, Informational Intervention, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Sarcoma
12/25
12/25
Bose, Prithviraj
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting
2/3
463
Europe, US, RoW
Elenestinib, BLU-263, Placebo
Blueprint Medicines Corporation
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
06/28
06/28
NCT02784496: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Completed
2
8
US
Long-term Follow-up, Quality-of-Life Assessment, Quality of Life Assessment, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Myelofibrosis
01/24
01/24
NCT04517851: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Active, not recruiting
2
15
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Questionnaire Administration
M.D. Anderson Cancer Center
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
12/25
12/25
NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting
1/2
150
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
09/26
09/26
NCT06343805: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Recruiting
1
76
US
AJ1-11095
Ajax Therapeutics, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, PMF, PPV-MF, PET-MF
10/26
02/27
Conley, Anthony P
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

Recruiting
2
26
US
Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma
12/18
12/18
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
BETA-PRIME, NCT04673942: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Recruiting
2
140
US
AdAPT-001, Checkpoint Inhibitor, Immune
EpicentRx, Inc.
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
12/25
03/27
NCT05041127: Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Recruiting
2
15
US
Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Questionnaire Administration
M.D. Anderson Cancer Center
Chordoma, Metastatic Chordoma, Unresectable Chordoma
09/26
09/26
NCT05333458: Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

Recruiting
2
77
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
National Cancer Institute (NCI)
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
05/25
05/25
ZIABC011078, NCT03141684: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Hourglass Oct 2024 - Dec 2024 : Regulatory approval for alveolar soft part sarcoma
Active, not recruiting
2
63
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
10/25
10/25
NCT04278781: AG-120 in People With IDH1 Mutant Chondrosarcoma

Active, not recruiting
2
6
US
AG-120
Memorial Sloan Kettering Cancer Center, Agios Pharmaceuticals, Inc.
Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation
03/26
03/26
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Active, not recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
12/25
12/25
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors

Recruiting
1
33
US
CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto
Imugene Limited
Solid Tumor, Adult
06/27
05/29
Baratam, Praneeth
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
SGNS70-101, NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
Ali, Moaath Mustafa
NCT05532722: ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Active, not recruiting
1/2
21
US
ABC008
Abcuro, Inc.
T-cell Large Granular Lymphocytic Leukemia
09/25
09/27
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
53
US
GDX012, Chemotherapy Agents
Takeda
Leukemia
04/26
06/27
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Active, not recruiting
1
63
US
NC525
NextCure, Inc.
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
05/25
05/25

Download Options